"Shares in Incyte have leaped after the company reported positive results for its epacadostat—vying to be the first-in-class IDO1 inhibitor—alongside Merck's PD-1 blocker Keytruda."
http://www.fiercebiotech.com/biotec...kid=4637628&utm_medium=nl&utm_source=internal
.